Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.48 USD | -1.79% | +8.73% | +29.86% |
Financials (USD)
Sales 2024 * | 194M | Sales 2025 * | 232M | Capitalization | 319M |
---|---|---|---|---|---|
Net income 2024 * | -3M | Net income 2025 * | -19M | EV / Sales 2024 * | 0.67 x |
Net cash position 2024 * | 189M | Net Debt 2025 * | 65.1M | EV / Sales 2025 * | 1.65 x |
P/E ratio 2024 * |
-91.3
x | P/E ratio 2025 * |
-16.6
x | Employees | 203 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.01% |
Latest transcript on Vanda Pharmaceuticals Inc.
1 day | -1.79% | ||
1 week | +8.73% | ||
Current month | +15.13% | ||
1 month | +10.26% | ||
3 months | +25.11% | ||
6 months | +54.37% | ||
Current year | +29.86% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 64 | 02-10-31 | |
Kevin Moran
DFI | Director of Finance/CFO | 40 | 12-11-30 |
Scott Howell
HRO | Human Resources Officer | - | 19-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Dugan
BRD | Director/Board Member | 82 | 05-11-30 |
Chief Executive Officer | 64 | 02-10-31 | |
Stephen Mitchell
BRD | Director/Board Member | 72 | 20-02-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.34% | 28 M€ | -0.48% | ||
0.22% | 25 M€ | -1.43% | - | |
0.05% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 5.48 | -1.79% | 788,121 |
24-05-16 | 5.58 | +4.10% | 1,093,025 |
24-05-15 | 5.36 | +4.48% | 908,363 |
24-05-14 | 5.13 | +1.58% | 774,501 |
24-05-13 | 5.05 | +0.20% | 833,009 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.86% | 319M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- VNDA Stock